Narmafotinib - Amplia Therapeutics
Alternative Names: AMP-945; CTX-0294945Latest Information Update: 07 Feb 2025
Price :
$50 *
At a glance
- Originator Cancer Therapeutics CRC; Cytopia Inc
- Developer Amplia Therapeutics
- Class Acetamides; Amines; Antifibrotics; Antineoplastics; Fluorinated hydrocarbons; Hepatoprotectants; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Preclinical Fibrosis; Non-alcoholic steatohepatitis; Ovarian cancer
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 03 Feb 2025 Efficacy data from the phase Ib/IIa ACCENT trial released by Amplia Therapeutics Limited
- 03 Feb 2025 Amplia Therapeutics completes enrolment in phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in Australia and South Korea (PO) (NCT05355298)
- 23 Sep 2024 Efficacy and adverse event data from the phase Ib/IIa ACCENT trial released by Amplia Therapeutics Limited